Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.8M
-
Number of holders
-
119
-
Total 13F shares, excl. options
-
48M
-
Shares change
-
-1.16M
-
Total reported value, excl. options
-
$430M
-
Value change
-
-$11.5M
-
Put/Call ratio
-
1.64
-
Number of buys
-
48
-
Number of sells
-
-61
-
Price
-
$8.97
Significant Holders of Theravance Biopharma, Inc. - Common Stock (TBPH) as of Q1 2024
138 filings reported holding TBPH - Theravance Biopharma, Inc. - Common Stock as of Q1 2024.
Theravance Biopharma, Inc. - Common Stock (TBPH) has 119 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 48M shares
of 49.8M outstanding shares and own 96.34% of the company stock.
Largest 10 shareholders include Weiss Asset Management LP (7.46M shares), Madison Avenue Partners, LP (7.01M shares), BAUPOST GROUP LLC/MA (6.59M shares), BlackRock Inc. (4.21M shares), Irenic Capital Management LP (2.76M shares), VANGUARD GROUP INC (2.69M shares), PICTET ASSET MANAGEMENT Holding SA (2.04M shares), Newtyn Management, LLC (1.64M shares), STATE STREET CORP (1.37M shares), and Oasis Management Co Ltd. (1.16M shares).
This table shows the top 119 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.